Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Generalitat de Catalunya | UNKNOWN |
| European Union | OTHER |
Not provided
Not provided
Not provided
Not provided
Caffeine is one of the few supplements that have enough scientific evidence to state that can notably improve performance, as different remarkable organizations in the sports nutrition context have classified it as an ergogenic aid with strong evidence regarding its efficacy and that is apparently safe. The beneficial effect of this substance on physical and cognitive performance has been identified in aerobic and anaerobic efforts, including aerobic and muscular endurance, power, or strength.
However, it seems that the benefits of caffeine are usually measured only by its effect on performance, while a comprehensive analysis of its impact on other aspects of the movement technique of the exercise is not considered. Therefore, although caffeine generates better performance, a null or negative effect may occur on technique execution. As such, some consequences might arise (e.g., an increase in injury risk or a decrease in energy efficiency).
The objective of this randomized controlled trial is to assess the influence of caffeine on certain biomechanical parameters of the technique of physical exercises in circumstances without fatigue and under neuromuscular fatigue. The study hypothesis is that caffeine generates modifications in the technical execution of certain movements in fatigued and unfatigued circumstances due to its physiological effects, which may be beneficial for performance and injury prevention.
The participants will have to attend 5 sessions (enrollment, familiarization, control, placebo, and caffeine), at least 7 days apart. In the last 3 sessions, different measurements will be done to their technique while jumping, squatting, and running, without fatigue and with it. Other data will be collected throughout the study to contextualize and analyze in more detail the obtained information.
A detailed description of the study can be found in the protocol uploaded with this registry entry.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Control - caffeine - placebo. | Experimental | The order of the assessed sessions will be first the control one, then the caffeine one, and then the placebo one. |
|
| Control - placebo - caffeine. | Experimental | The order of the assessed sessions will be first the control one, then the placebo one, and then the caffeine one. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Caffeine. | Dietary Supplement | Ingestion of opaque capsules with a total dose of 6mg/kg of caffeine, 60 minutes before the beginning of the assessed exercises. A crossover with the other intervention will be done in the next/previous session (depending on the arm). |
| Measure | Description | Time Frame |
|---|---|---|
| Knee flexion angle at the midstance while running. | Assessment of the knee flexion angle (in degrees). The measurement will be done before and after a fatiguing protocol. Assessed using kinematic instruments. | During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours. |
| Ankle dorsiflexion angle at the midstance while running. | Assessment of the ankle dorsiflexion angle (in degrees). The measurement will be done before and after a fatiguing protocol. Assessed using kinematic instruments. | During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours. |
| Step rate while running. | Assessment of the step rate (in steps/minute). The measurement will be done before and after a fatiguing protocol. Assessed using kinematic instruments. | During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours. |
| Contact time while running. | Assessment of the time the foot is in contact with the ground (in seconds). The measurement will be done before and after a fatiguing protocol. Assessed using kinematic instruments. | During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours. |
| Stride length while running. | Assessment of the distance between two successive placements of the same foot (in meters). The measurement will be done before and after a fatiguing protocol. Assessed using kinematic instruments. | During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours. |
| Measure | Description | Time Frame |
|---|---|---|
| Supplementation identification. | Assessment of the participants' perception regarding the ingested substance. They will have to complete a questionnaire immediately before (1 hour post-supplementation) and after the assessed exercises, indicating what substance they believe that they have consumed, with the options "caffeine", "placebo", or "I don't know", as well as the reason why they have chosen that answer. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Arnau Baena Riera, MSc. | Sport, Exercise, and Human Movement (SEaHM), University of Vic - Central University of Catalonia. | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Vic - Central University of Catalonia. | Vic | Barcelona. | 08500. | Spain |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Aug 15, 2023 | Aug 16, 2023 | Prot_000.pdf |
Not provided
| ID | Term |
|---|---|
| D005221 | Fatigue |
| D014947 | Wounds and Injuries |
| D009043 | Motor Activity |
| ID | Term |
|---|---|
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D001519 | Behavior |
Not provided
Not provided
| ID | Term |
|---|---|
| D002110 | Caffeine |
| D002482 | Cellulose |
| ID | Term |
|---|---|
| D014970 | Xanthines |
| D000470 | Alkaloids |
| D006571 | Heterocyclic Compounds |
| D011688 | Purinones |
Not provided
Not provided
The assessed sessions, which will be identical, will be the control, the caffeine, and the placebo ones. The last two sessions mentioned will be performed in a randomized order.
Not provided
Not provided
The placebo and the caffeine ingestion protocols will be identical in format and presentation. To minimize any influence of the flavor or the look of the ingested substance, both conditions will imply the consumption of opaque capsules (ingested with water) in which there will be 6mg/kg of caffeine or placebo.
| Cellulose. | Drug | Ingestion of opaque capsules with cellulose, 60 minutes before the beginning of the assessed exercises. A crossover with the other intervention will be done in the next/previous session (depending on the arm). |
|
|
| Flight time while running. | Assessment of the time the foot is not in contact with the ground (in seconds). The measurement will be done before and after a fatiguing protocol. Assessed using kinematic instruments. | During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours. |
| Running performance modification. | Assessment of the time (in seconds) required to complete a specific distance running on a treadmill. The measurement will be done before and after a fatiguing protocol. Assessed using a stopwatch. | During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours. |
| Hip angle while squatting, at the initial position, bottom position, and final position, and the eccentric and the concentric range of movement. | Assessment of the hip angle (in degrees). The measurement will be done before and after a fatiguing protocol. Assessed using kinematic instruments. | During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours. |
| Knee angle while squatting, at the initial position, bottom position, and final position, and the eccentric and the concentric range of movement. | Assessment of the knee angle (in degrees). The measurement will be done before and after a fatiguing protocol. Assessed using kinematic instruments. | During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours. |
| Ankle angle while squatting, at the initial position, bottom position, and final position, and the eccentric and the concentric range of movement. | Assessment of the ankle angle (in degrees). The measurement will be done before and after a fatiguing protocol. Assessed using kinematic instruments. | During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours. |
| Execution time while squatting, for the eccentric and the concentric phases of the movement. | Assessment of the execution time to perform the eccentric and the concentric phases of the squat (in seconds). The measurement will be done before and after a fatiguing protocol. Assessed using a linear position transducer. | During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours. |
| Peak vertical force while squatting, for the eccentric and the concentric phases of the movement. | Assessment of the peak vertical force (in Newtons). The measurement will be done before and after a fatiguing protocol. Assessed using a linear position transducer. | During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours. |
| Rate of force development while squatting, for the eccentric and the concentric phases of the movement. | Assessment of the rate of force development (in Newtons/seconds). The measurement will be done before and after a fatiguing protocol. Assessed using a linear position transducer. | During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours. |
| Squatting performance modification. | Assessment of the mean propulsive bar velocity (in meters/seconds) for a specific weight lifted in barbell back squats. The measurement will be done before and after a fatiguing protocol. Assessed using a linear position transducer. | During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours. |
| Contralateral pelvic drop angle while jumping, at the initial contact of the landing phase. | Assessment of the contralateral pelvic drop angle (in degrees). The measurement will be done before and after a fatiguing protocol. Assessed using kinematic instruments. | During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours. |
| Knee valgus while jumping, at the initial contact and the deepest landing position of the landing phase, and the range of movement between these two moments. | Assessment of the knee valgus angle (in degrees). The measurement will be done before and after a fatiguing protocol. Assessed using kinematic instruments. | During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours. |
| Unweighting phase duration while jumping (jumping phase). | Assessment of the unweighting phase duration (in seconds). The measurement will be done before and after a fatiguing protocol. Assessed using force plates. | During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours. |
| Braking phase duration while jumping (jumping phase). | Assessment of the braking phase duration (in seconds). The measurement will be done before and after a fatiguing protocol. Assessed using force plates. | During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours. |
| Propulsive phase duration while jumping (jumping phase). | Assessment of the propulsive phase duration (in seconds). The measurement will be done before and after a fatiguing protocol. Assessed using force plates. | During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours. |
| Relative peak power output while jumping (jumping phase). | Assessment of the relative peak power output (in Watts/kg). The measurement will be done before and after a fatiguing protocol. Assessed using force plates. | During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours. |
| Jumping performance modification. | Assessment of the height (in meters) of countermovement jumps. The measurement will be done before and after a fatiguing protocol. Assessed using force plates. | During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours. |
| During the placebo and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours. |
| Side effects. | Assessment of the participant's side effects related to caffeine consumption. In the morning of the day after the sessions, they will be requested to complete a questionnaire comprised of 8 questions with a yes/no answer, to evaluate the side effects of caffeine consumption during the hours after the sessions. | During the day after the placebo and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours. |
| D011687 |
| Purines |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D005936 | Glucans |
| D001704 | Biopolymers |
| D011108 | Polymers |
| D046911 | Macromolecular Substances |
| D011134 | Polysaccharides |
| D002241 | Carbohydrates |
| D001697 | Biomedical and Dental Materials |
| D008420 | Manufactured Materials |
| D013676 | Technology, Industry, and Agriculture |